Design of Nanoparticles as Drug Carriers for Cancer Therapy

Cancer Genomics - Proteomics

BENOIT SIMARD²  YVES DESLANDES³  MICHAEL POST³  TSUNG HAN HSIEH¹  CHRISTOPHER Q. LAN¹  JIN ZHANG¹ 

[1] epartment of Chemical Engineering, University of Ottawa, Ottawa, Ontario, K1N 6N5epartment of Chemical Engineering, University of Ottawa, Ottawa, Ontario, K1N 6N5epartment of Chemical Engineering, University of Ottawa, Ottawa, Ontario, K1N 6N5;teacie Institute for Molecular Sciences, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canadateacie Institute for Molecular Sciences, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canadateacie Institute for Molecular Sciences, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada;nstitute for Chemical Process and Environmental Technology, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canadanstitute for Chemical Process and Environmental Technology, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canadanstitute for Chemical Process and Environmental Technology, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada

关键词: Drug delivery;    cancer chemotherapy;    nanoparticles;    polymer- and liposome-systems;    magnetic nanohybrids;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

This review explores the recent chemotherapeutic work on drug delivery using nanoparticles as carriers for the targeted treatment of cancer. Compared to direct drug delivery, delivery through a carrier can increase the efficacy of a drug, but decrease the side-effects by utilizing the enhanced permeability and retention (EPR) effect and tumor-specific targeting. The search for efficient and safe transport vehicles (carriers) to achieve better drug availability at the target site has been a challenging yet exciting area of research. Current interest focuses on the colloidal nanoparticles (diameter <500 nm), including the biodegradable polymer- and liposome-systems, bioconjugating with antitumor drugs. These biocompatible nanoparticles, with an enlarged surface area-volume ratio can overcome non-cellular and cellular-based mechanisms of resistance and increase the selectivity of drugs towards cancer cells, while reducing their toxicity towards normal tissues. This review focuses on the evolution of nanoparticles as carriers for anticancer drug delivery, with emphasis on the biocompatible magnetic nanohybrids.

【 授权许可】

Unknown